Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

109.80 -0.45 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,661,718
Open 110.15
Bid (Size) 109.80 (10)
Ask (Size) 110.28 (1)
Prev. Close 110.25
Today's Range 109.75 - 110.22
52wk Range 57.84 - 117.49
Shares Outstanding 226,621,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
 
Via Benzinga

Performance

YTD
-3.26%
-3.26%
1 Month
-2.93%
-2.93%
3 Month
+42.45%
+42.45%
6 Month
+63.59%
+63.59%
1 Year
+17.10%
+17.10%

More News

Read More
Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short
Via Investor's Business Daily
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Via Benzinga
Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder
Via Benzinga
$1000 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
From Horizon Therapeutics plc
Via Business Wire
Rule 15 (c) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
From Kahn Swick & Foti, LLC
Via Business Wire
Rule 17 (b) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
A Bullish Sign Appears On Horizon Therapeutics's Chart
Via Benzinga
Rule 17 (a) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
From Horizon Therapeutics plc
Via Business Wire
Rule 2.12 Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
3 Biotech Companies to Watch in 2023
Via InvestorPlace
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
Via InvestorPlace
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
Via The Motley Fool
How Did 2022’s Most Loved Stocks By Analysts Fare?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.